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Abstract
Trib2 is highly expressed in human T cell acute lymphoblastic leukemia (T-ALL) and is a
direct transcriptional target of the oncogenic drivers Notch and TAL1. In human TAL1-driven
T-ALL cell lines, Trib2 is proposed to function as an important survival factor, but there is
limited information about the role of Trib2 in primary T-ALL. In this study, we investigated
the role of Trib2 in the initiation and maintenance of Notch-dependent T-ALL. Trib2 had no
effect on the growth and survival of murine T-ALL cell lines in vitro when expression was
blocked by shRNAs. To test the function of Trib2 on leukemogenesis in vivo, we generated
Trib2 knockout mice. Mice were born at the expected Mendelian frequencies without gross
developmental anomalies. Adult mice did not develop pathology or shortened survival, and
hematopoiesis, including T cell development, was unperturbed. Using a retroviral model of
Notch-induced T-ALL, deletion of Trib2 unexpectedly decreased the latency and increased
the penetrance of T-ALL development in vivo. Immunoblotting of primary murine T-ALL
cells showed that the absence of Trib2 increased C/EBPα expression, a known regulator of
cell proliferation, and did not alter AKT or ERK phosphorylation. Although Trib2 was sug-
gested to be highly expressed in T-ALL, transcriptomic analysis of two independent T-ALL
cohorts showed that low Trib2 expression correlated with the TLX1-expressing cortical
mature T-ALL subtype, whereas high Trib2 expression correlated with the LYL1-expressing
early immature T-ALL subtype. These data indicate that Trib2 has a complex role in the
pathogenesis of Notch-driven T-ALL, which may vary between different T-ALL subtypes.
Introduction
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy resulting
from the oncogenic transformation of T cell progenitors and accounting for 25% of adult and
15% of pediatric ALL cases [1]. Although intensified chemotherapy has markedly improved
long-term survival, survival following relapse is poor, highlighting the need for novel therapies
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in recurrent disease. Activating mutations of Notch1 occur in about 50% of T-ALL cases, most
of which occur in the heterodimerization domain (HD) and proline-glutamic acid- serine-thre-
onine (PEST) domains [2]. NOTCH1 is a potentially important therapeutic target in T-ALL
given the high prevalence of mutations and the significant role of NOTCH signaling in T-ALL.
Although inhibiting Notch in mouse models of T-ALL caused marked anti-leukemic effects in
vivo [3, 4], success in patients has met with difficulties, in part due to “on target” toxicity and
possible drug resistance [5]. Therefore, identifying downstream Notch effectors may lead to
the identification of novel therapeutic targets in T-ALL.
Previous studies identified Trib2, a member of the Tribbles protein family, as a direct tran-
scriptional target of Notch1 in T-ALL cell lines [6, 7]. Tribbles are an evolutionarily conserved
protein family that is implicated in diverse cellular events that include proliferation, migration,
metabolism, and oncogenic transformation (reviewed in [8]). Tribbles was first characterized
in Drosophila as an important cell cycle regulator [9]. In mammals, the Trib protein family
members Trib1, Trib2 and Trib3 are characterized by a conserved pseudokinase domain [10],
and COP1 [11] and MEK1 [12] binding domains. Trib proteins function as scaffolding mole-
cules that facilitate protein degradation via a proteasome-dependent mechanism. In mammals,
Trib1 and Trib2 promote C/EBPα degradation [6, 13] by recruiting the E3 ligase, COP1. Simi-
larly, Trib3 promotes COP1-dependent degradation of acetyl CoA carboxylase (ACC), an
enzyme involved in fatty acid synthesis [11]. The Trib proteins also modulate signaling path-
ways such as AKT [14] and MAPK [15]. Trib2 can inhibit AKT phosphorylation [16, 17] and
Trib proteins interact with MEK1 and enhance ERK phosphorylation [15] through the MEK1
binding motif [12].
Trib2 is highly expressed in human T-ALL and T cells [18]. In addition to its association
with Notch expression in T-ALL, a recent study showed that Trib2 is required for the growth
and survival of human T-ALL cell lines driven by TAL1 [19]. In contrast, we found that
shRNA-mediated knockdown of Trib2 in murine T-ALL cell lines did not affect cell growth or
survival. To investigate the importance of Trib2 in T cell development and in T-ALL pathogen-
esis in vivo, we generated Trib2 knockout mice. Our results show that global deletion of Trib2
had no obvious defects on mouse development or survival. In particular, T cell development
was normal. Strikingly, the absence of Trib2 resulted in a significant decrease in disease latency
and increased disease penetrance in a murine model of Notch-driven T-ALL. Tumor cells from
moribund mice expressed increased C/EBPα protein, while no change was seen in the amounts
of phosphorylated AKT or ERK. Taken together, these data indicate that the influence of Trib2
expression on T cell leukemogenesis may vary in different contexts; however, in murine T-
ALL, we identified an important role for Trib2 as a negative regulator of Notch-induced T-ALL
in vivo.
Results
Murine T-ALL cells do not depend on persistent Trib2 expression
In order to determine the importance of Trib2 in the maintenance of T-ALL, we investigated
the effect of Trib2 loss in T-ALL cell lines. A previous study identified Trib2 as an important
survival factor in human TAL1-driven T-ALL cell lines, including Jurkat [19]. Consistent with
these data, we observed a severe decrease in Jurkat cell growth (Fig 1A) due to apoptosis (Fig
1B) when Trib2 was knocked down (Fig 1C), suggesting an important role for Trib2 in the
growth/survival of these cells. Activating mutations in NOTCH1 occur in over 50% of human
T-ALLs [2]. Although Notch1 is mutated in Jurkat cells, growth and survival of these cells is
Notch-independent [20, 21]. As Trib2 is a direct Notch target in Notch-induced murine
T-ALL cells [7], we investigated the requirement for persistent Trib2 expression in these
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Notch-dependent cells. T6E cells [22], a murine Notch1-dependent T-ALL cell line, were trans-
duced with shRNAs targeting Trib2 or a scrambled control sequence. Unlike Jurkat cells, Trib2
knockdown did not affect cell growth or survival (Fig 1D and data not shown). To determine
if Trib2 dependency is specific for Tal1 expressing cell lines, we assayed the effects of Trib2
knockdown in TAL-130 cells, a T-ALL cell line derived from mice expressing a Tal1 transgene
[23]. Knockdown of Trib2 by shRNA in TAL-130 cells showed no changes in cell growth (Fig
1E) or survival (data not shown). Immunoblotting confirmed that TAL-130 cells express
higher levels of Tal1 than T6E cells (Fig 1F). Furthermore, both T6E and TAL-130 cells main-
tained Trib2 knockdown for at least 15 days after expressing the shRNA (Fig 1G and 1H), indi-
cating that neither cell line requires Trib2 for proliferation or survival. Together, these data
Fig 1. Trib2 is not required to maintain murine T-ALL cell lines. Jurkat cells were transduced with normalized viral particles to express shRNAs against
Luciferase (shLuc) or Trib2 (shTrib2) along with a GFP reporter. A) The percentage of GFP+ cells within the population was monitored for 7 days post-
infection. B) At 3 days post-transduction, apoptosis was measured by Annexin V staining (“*”, p = 0.018) and C) Trib2 expression was measured by qPCR 3
days post-transduction in sorted GFP+ cells. Errors bars represent the standard deviation of biological replicates. D) T6E cells were transduced with
shRNAs against a scrambled sequence (shScrambled) or Trib2 (shTrib2) and GFP as a surrogate marker. GFP+ cells were sorted 48 hours after
transduction (day 0) and growth was monitored. E) TAL-130 cells were transduced with shRNAs against a scrambled sequence (shScrambled) or Trib2
(shTrib2) and GFP as a surrogate marker. GFP+ cells were sorted 48 hours after transduction (day 0) and growth was monitored. F) TAL1 expression was
measured in T6E and TAL-130 cells by immunoblot. Jurkat lysates were used as a positive control. G & H) Trib2 expression was measured at days 0 and 15
in T6E (Panel G) or TAL-130 cells (Panel H). Error bars indicate standard deviation. Data are representative of 3 experiments.
doi:10.1371/journal.pone.0155408.g001
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indicate that the requirement for persistent Trib2 expression varies between different T-ALL
cell lines.
Absence of T cell defects in Trib2 knockout mice
Trib2 is highly expressed in developing murine T cells and murine and human T-ALLs [18].
We therefore generated a genomic Trib2 knockout mouse to determine the importance of
Trib2 in T cell development and disease initiation. LoxP sites flanking exon 2 of Trib2 were
inserted into a targeting vector and germline transmission was achieved through homologous
recombination. The mice were subsequently crossed to FLP1-transgenic mice to remove the
neomycin cassette and then backcrossed for greater than 8 generations to the C57BL/6 back-
ground (Fig 2A). Mice were born at the expected Mendelian frequencies without gross develop-
mental anomalies (data not shown). Adult mice did not develop pathology or shortened
survival (data not shown). Deletion of exon 2 of Trib2 was confirmed by PCR genotyping of
genomic DNA from offspring (Fig 2B). Trib2 mRNA and protein expression was not detected
in Trib2-/- thymocytes as compared to Trib2+/+ or Trib2+/- littermate controls (Fig 2C and 2D).
Trib2mRNA expression increases throughout T cell differentiation from T lineage precur-
sors to mature, resting T cells (Fig 3A). We therefore analyzed the effect of Trib2 loss in both
developing T cells and early hematopoietic progenitor populations in the bone marrow. Dele-
tion of Trib2 did not affect the percentage of hematopoietic stem cells or progenitors in the
bone marrow (S1A and S1B Fig). Additionally, the survival of Trib2-/- mice did not differ from
Trib2+/+ littermates in response to serial 5-fluorouracil treatment, suggesting an equivalent
response to stress (S1C Fig). Immunophenotyping by flow cytometry showed no differences in
the percentage or absolute numbers of T-lineage committed thymocytes (Fig 3B and 3C). Fur-
thermore, no difference in the percentage or numbers of CD4/CD8 double negative cells at
each stage of development was observed (Fig 3D and 3E). Additional data showed no difference
in the percentage or numbers of CD19+ B cells or CD3+ T cells in the spleen (Fig 3F and 3H) or
peripheral blood (data not shown) of Trib2-/- mice. Finally, no difference in the percentage or
numbers of CD4 or CD8-expressing T cells was observed in the spleens of mice lacking Trib2
(Fig 3G and 3H). In addition, there did not appear to be compensatory changes in either Trib1
or Trib3 expression in Trib2-deficient thymocytes (Fig 3I). Thus, Trib2 absence does not
impair T cell development.
Trib2 absence decreases latency and increases penetrance of Notch-
induced T-ALL
As Trib2 absence did not affect steady-state T cell development, we employed a murine T-ALL
model to determine the importance of Trib2 in disease pathogenesis. Hematopoietic stem and
progenitor cells from either Trib2-/- or wild-type (Trib2+/+) controls were transduced with
retroviral supernatants expressing oncogenic forms of Notch along with GFP as a surrogate
marker [24]. The cells were then injected into lethally irradiated syngeneic C57BL/6 recipients.
Two different forms of oncogenic Notch were used for these studies; Notch1 L1601PΔP
expresses a full length Notch1 allele that contains a destabilizing mutation in the HD domain
and lacks the regulatory PEST domain, whereas ICN1 (intracellular Notch1) encodes only the
intracellular Notch1 domain [24]. Notch1 L1601PΔP exhibits weaker activity than ICN1 in
Notch1 reporter assays and induces T-ALL with longer latency and reduced penetrance [24].
Mice receiving Trib2-/- cells expressing ICN1 succumbed to T-ALL more quickly than their
wild-type counterparts, with a median survival of 40 and 47.5 days, respectively (Fig 4A).
Despite a decrease in survival time, the absence of Trib2 did not affect the expression of CD4
and CD8 on the surface of leukemic cells (Fig 4B). Additionally, moribund recipient mice
Trib2 Suppresses T-ALL
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showed similar spleen weights (Fig 4C), white blood cell counts (WBC; Fig 4D) and immature
blast morphology (Fig 4E). The leukemic cells filled the spleen, obliterating the normal splenic
architecture (Fig 4E). Leukemic cells from both Trib2-/- and Trib2+/+ donors also filled the
bone marrow and infiltrated non-hematopoietic organs, such as liver and lung (data not
shown). Consistent with previous results [24], L1601PΔP induced a partially penetrant pheno-
type with approximately 40% of the mice receiving Trib2+/+ cells transduced with L1601PΔP
succumbing to T-ALL with a median survival of 97 days. In contrast, all of the mice receiving
Trib2-/- cells transduced with L1601PΔP developed leukemia with a median survival of 75 days
(Fig 4F). When comparing the mice that developed leukemia induced by L1601PΔP, no differ-
ence was observed between the Trib2+/+ and the Trib2-/- mice with regards to CD4 and CD8
expression on the leukemic cells (Fig 4G) or spleen weights (Fig 4H). Moribund Trib2-/- recipi-
ents had significantly higher WBCs than the control group (Fig 4I). The immature blast histo-
pathology of these T-cell leukemias was similar to that previously reported [24] and between
the two groups (Fig 4J and not shown). The leukemic cells were capable of serial transfer;
Fig 2. Generation and characterization of Trib2 null mice. A) The targeting strategy to delete Trib2 exon 2 is shown. B) The deletion of the targeted region
is shown by PCR performed on tail genomic DNA. C) qPCR; and D) immunoblot showing the deletion of Trib2 mRNA and protein in mouse thymocytes. Error
bars indicate standard deviation.
doi:10.1371/journal.pone.0155408.g002
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however, mice receiving sorted Trib2-/- cells expressing either ICN or L1601PΔP succumbed to
leukemia more quickly than those receiving sorted Trib2+/+ cells (S3 Fig). Thus, the absence of
Trib2 increases the penetrance and decreases the latency of Notch1-induced T-ALL.
Absence of Trib2 is associated with increased C/EBPα expression in
T-ALL cells
Trib2 regulates multiple signaling pathways including AKT [14, 16], MAPK [15] and C/EBPα
[6]. There are two C/EBPα isoforms, p42 and p30, that are derived from post-transcriptional
processing of a single transcript [25, 26]. C/EBPα p42 is anti-proliferative, whereas p30 is
Fig 3. Deletion of Trib2 does not affect T cell development. A) Levels of Trib2 expression throughout T cell development as determined in the Immgen
microarray data set are shown. B) Thymic subsets were analyzed by flow cytometry for CD4 and CD8 expression. Representative scatter plots (B) and C)
graphs depicting the absolute numbers and percentages of cells in the total population are shown (n = 5–6 mice per group). D) CD4−CD8− double negative
thymocytes were further assessed for the surface expression of CD44 and CD25. Representative scatter plots and E) graphs depicting the percentages and
absolute numbers of cells in the total population are shown (n = 3 mice per group). F) The surface expression of CD3 and CD19, and G) CD4 and CD8 on
splenocytes was assessed (n = 6 mice per group). H) Representative scatter plots and graphs depicting the percentages and absolute numbers of cells in
the total splenocyte population are shown (n = 6 mice per group). Error bars indicate standard deviation. I) The expression of Trib1 and Trib3 were measured
by qPCR (n = 3 per group).
doi:10.1371/journal.pone.0155408.g003
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proliferative and a decrease in the p42/p30 ratio is associated with tumorigenesis [27, 28]. In
myeloid cells, retroviral Trib2 expression decreased the p42/p30 ratio [6]. In the Trib2-defi-
cient T-ALL cells, C/EBPα was markedly increased. Both the p42 and p30 isoforms were
increased; however, p30 remained greater than p42 (Fig 5A). Despite a substantial increase in
protein levels, the C/EBPα target genesMpo [29], Ltf [30], and Lyz2 [31] remained undetect-
able in sorted tumor cells from Trib2+/+ and Trib2-/- mice, and expression of the myeloid
Fig 4. Loss of Trib2 decreases disease latency of Notch-driven T-ALL. A) Kaplan-Meier curve of lethally irradiated mice reconstituted with Trib2+/+ or
Trib2-/- cells expressing intracellular Notch1 (ICN; “***”, p = 0.0002). Mice with a body condition score of2 and decreased mobility were euthanized (n = 8
Trib2+/+ and n = 12 Trib2-/- recipients. B) Flow cytometry was used to assess the immunophenotype of leukemic cells in the spleen. C) Spleen weights and D)
WBC of moribund mice are shown. E) Representative H&E staining of spleens harvested frommoribund mice (left panels, 10X magnification, scale
bar = 50μM; right panels, 100Xmagnification, scale bar = 10μM). F) Kaplan-Meier curve of lethally irradiated mice reconstituted with Trib2+/+ or Trib2-/- cells
expressing the weakly oncogenic Notch mutant, Notch 1 L1601PΔP (“****”, p<0.0001), (n = 16 Trib2+/+ and n = 7 Trib2-/- recipients). G) Flow cytometry was
used to assess the immunophenotype of leukemic cells in the spleen. H) Spleen weights and I) WBC of moribund mice are shown (“*”, p = 0.013). J) H&E
staining of spleens frommoribund mice (left panels, 10X magnification, scale bar = 50μM; right panels, 100Xmagnification, scale bar = 10μM).
doi:10.1371/journal.pone.0155408.g004
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marker Itgam did not change (data not shown). Phosphorylated ERK was not detectable in
either group (Fig 5B) and no change in AKT phosphorylation was observed between Trib2-/-
and Trib2+/+ tumor cells expressing ICN1 (Fig 5C). Together, these data implicate Trib2 as a
suppressor of disease initiation in Notch-driven T-ALL through a process that may involve
C/EBPα.
Absence of Trib2 does not affect AML induction by MLL-AF9
One potential explanation for the decreased latency of Notch-induced T-ALL in the Trib2-null
cells was that the hematopoietic progenitors were more susceptible to retroviral transduction. To
address this possibility, we used the MLL-AF9 retroviral model of AML induction [32]. We used
identical methods to those used for the Notch bone marrow experiments with the exception that
the MigR1 retrovirus expressed MLL-AF9. In contrast to Notch-induced T-ALL, absence of
Trib2 did not decrease disease latency in this model. Instead, there was a slight increase in disease
latency with a median survival of 62 days or 71 days for recipients of Trib2+/+ or Trib2-/- cells,
Fig 5. C/EBPα expression increases in the absence of Trib2 in primary tumor cells expressing oncogenic Notch. Immunoblotting was used to
visualize A) the expression of C/EBPα, and B) the phosphorylation status of ERK in Trib2+/+ or Trib2-/- splenocytes of moribund mice. Percentage of GFP+
cells in each sample; Lane 1: 71, Lane 2: 66, Lane 3: 57, Lane 4: 65, Lane 5: 71, Lane 6: 42. Whole bone marrow (WBM) (A) or Jurkat cells stimulated with
PMA (B) were used as controls. In Panel A, lighter and darker exposures are provided. C) The phosphorylation status of AKT (pS473 AKT) was determined
by immunoblot in GFP+ sorted splenocytes frommoribund mice.
doi:10.1371/journal.pone.0155408.g005
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respectively (Fig 6A). Both groups showed splenomegaly (Fig 6B) and increasedWBCs (Fig 6C),
while the animals that received empty vector were not affected (S2 Fig). The cells were largely
Gr1+CD11b+ immature myeloid blasts that infiltrated multiple organs and filled the bone mar-
row (Fig 6D and 6E and data not shown). Thus, the decreased latency observed in the Notch
T-ALL model is specific to T-ALL and not a general feature of leukemia induction in retroviral
models transducing Trib2-null donor cells.
Trib2 expression correlates with different T-ALL subtypes
Our finding that absence of Trib2 promoted Notch-induced T-ALL was surprising as TRIB2
expression correlates with activated NOTCH1 in primary patient tumor samples [18]. T-ALL is
not a uniform disease; instead, molecular profiling revealed signatures that specify different
subtypes. Primary samples from two separate datasets (GSE13159 and GSE26713 including
adult and pediatric T-ALL samples, respectively) were identified based on the expression of the
oncogenes TLX1, LYL1 and TAL1, and grouped based on unique expression profiles, which
correlate with recognized stages of normal thymocyte development; LYL1+ samples resemble
Fig 6. Trib2 does not suppress the initiation of MLL-AF9-drivenmyeloid leukemia. A) Kaplan-Meier curve of lethally irradiated mice reconstituted with
Trib2+/+ or Trib2-/- cells expressing MLL-AF9. Mice with a body condition score of2 and decreased mobility were euthanized (n = 5 per group). B) Spleen
weights and C) WBC of moribund mice are shown. D) Flow cytometry was used to assess the immunophenotype of leukemic cells in the spleen. E) H&E
staining of spleens harvested frommoribund mice (left panels, 10X magnification, scale bar = 50μM; right panels, 100X magnification, scale bar = 10μM).
doi:10.1371/journal.pone.0155408.g006
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thymocytes in the pre-T double negative stage of development, while TLX1+ and TAL1+ sam-
ples resemble thymocytes at the early and late cortical stages, respectively [33]. To determine
whether TRIB2 expression varied between subtypes, we correlated the level of TRIB2 expres-
sion with the gene signatures of T-ALL molecular subtypes. The Gene Set Enrichment Analysis
(GSEA) [34] analysis revealed a marked enrichment of the TLX1+ gene signature (cortical
mature T-ALL) in low TRIB2 expressing T-ALL patients (Fig 7A, 7B, 7E and 7F), whereas the
gene signature of LYL1+ (early immature T-ALL) significantly associated with samples express-
ing high levels of TRIB2 (Fig 7A, 7C, 7E and 7G). Interestingly, the gene signature of the
TAL1+ T-ALL subtype (late cortical T-ALL) did not significantly correlate with the TRIB2
expression status (Fig 7D and 7H). Of particular significance, these correlations held true
across two independent cohorts of T-ALL patients, including 174 adult (Fig 7A–7D) and 117
pediatric samples (Fig 7E–7H), respectively [35, 36]. Thus, these data suggest that Trib2
expression varies across human T-ALL subtypes.
Discussion
Our data show an important role for Trib2 in the induction of T-ALL by oncogenic Notch.
While Trib2 is not required to maintain either a Notch-induced or a Tal1-induced murine
T-ALL cell line, disease latency was decreased in mice transplanted with Trib2-/- cells express-
ing both strong and weak oncogenic Notch1 alleles. The weak oncogenic Notch1 allele
L1601PΔP induced T-ALL in ~40% of mice with increased survival time relative to ICN1 when
expressed in wild-type BM progenitors. However, when expressed in Trib2-deficient progeni-
tors, penetrance increased to 100% while survival decreased compared to the wild-type con-
trols. Together, these data suggest that Trib2 suppresses T-ALL pathogenesis. One possible
explanation for our data is that the hematopoietic progenitors lacking Trib2 are more suscepti-
ble to retroviral transduction. If so, we would predict that leukemia survival would be reduced
regardless of the oncogenic driver. This does not seem to be the case, however, as transduction
of Trib2-deficient cells with the myeloid oncogene, MLL-AF9, did not decrease leukemia
latency. This suggests that the decrease in leukemia survival is not a general property of Trib2-
deficient hematopoietic progenitors.
In contrast to the effects of Trib2 absence on leukemogenesis, we did not observe effects on
thymocyte development. This was somewhat surprising as the amount of active Notch1 in
DN3 cells is similar to the amount in T-ALL cells [37], and Trib2 is relatively highly expressed
(at least compared to Trib1 and Trib3) during T cell development. Of particular relevance to
our study, defects were not observed in the DN3 to DP populations that are suggested to con-
tain the leukemic stem cells in different models of Notch1-induced T-ALL [4, 38–40]. In addi-
tion to the thymus, the splenic CD4+ and CD8+ populations were present in the expected
ratios; however, we cannot rule out the possibility that T cell function may be perturbed in the
absence of Trib2.
Given the relatively high expression of Trib2 in developing T cells and its positive correla-
tion with human T-ALL [18], we were surprised to find that Trib2 functioned as a tumor
suppressor in our murine Notch1-induced T-ALL model. This led us to investigate Trib2
expression in the different subtypes of human T-ALL. The results from two independent
T-ALL cohorts showed that TRIB2 was negatively correlated with the TLX1+ gene signature
(cortical mature T-ALL) and positively correlated with the LYL1+ gene signature (early imma-
ture T-ALL). Interestingly, many of the genes associated with the expression of TLX1 are
involved in cell growth and proliferation, includingMYC [33]. Additional work is required to
understand the implications of these associations.
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Fig 7. TRIB2 expression correlates with the gene signatures of human early immature and cortical mature T-ALL subtypes. A) Adult T-ALL
samples with low (mean-SD) and high (mean+SD) TRIB2 gene expression (average of 202478_at and 202470_s_at) were identified in the GSE13159
dataset. Dashed lines indicate mean-SD and mean+SD of TRIB2 gene expression. B, C) GSEA analysis shows enrichment of gene signatures of the
Trib2 Suppresses T-ALL
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Although weak activating Notch1 mutations including L1601PΔP are frequent in human
T-ALL [2], few cooperating events that result in increased disease penetrance in vivo have been
identified. Similar to our data showing that the loss of Trib2 results in disease penetrance of
100%, the absence of the tumor suppressor PTEN [41] or expression of oncogenic KRAS [24]
both increase penetrance and decrease the latency of T-ALL induced by L1601PΔP. It remains
to be determined whether the comparable effects on L1601PΔP-mediated disease are due to
similar mechanisms by these different perturbations.
Previous studies suggest that Trib proteins can function as both dominant oncogenes [6,
42, 43] and tumor suppressors [44]. Trib3 was shown to enhance the tumorigenicity of a
variety of tumor cell lines and xenografts via a mechanism that involved dysregulation of
AKT phosphorylation by the mTORC2 complex and subsequent inactivation of the tran-
scription factor FOXO3 [44]. Trib1 and Trib2 are also implicated as tumor suppressors in
some subtypes of AML through inhibition of JNK signaling [45]. In contrast, Trib2 transfor-
mation in a murine AML model depends on C/EBPα degradation by a COP1-dependent
mechanism. The overexpression of Trib2 in AML does not result in total C/EBPα degrada-
tion in the tumor cells; instead, there appears to be preferential degradation of the p42 C/
EBPα isoform that results in a relative increase in expression of the p30 C/EBPα isoform
[6]. The two C/EBPα isoforms are generated by post-transcriptional processes [25, 26] and
differ in their amino termini; the N-terminal region unique to p42 contains transactivation
elements that interact with transcriptional machinery. The two isoforms share a common C-
terminal region that interacts with the chromatin remodeling complex and other transcrip-
tion factors [46]. Functionally, C/EBPα p42 is anti-proliferative via its suppression of E2F.
Conversely, C/EBPα p30 is unable to interact with E2F resulting in unchecked proliferation
[27]. Expression of C/EBPα p30 in the absence of p42 is sufficient to induce AML in mice
through a mechanism involving loss of proliferative control in myeloid progenitor popula-
tions [28]. In developing T cells, C/EBPα transcription is repressed by the Notch target,
Hes1, which is important for T cell specification [47], a mechanism that may be reinforced
by Trib2-induced degradation of C/EBPα protein. Unlike the scenario in Trib2-induced
AML, the p42:p30 C/EBPα ratio is maintained in the Trib2-deficient leukemic T-ALL cells;
however, the major distinction is that there is much more total C/EBPα protein in the
absence of Trib2. One potential explanation is that the increased amount of C/EBPα pro-
motes the pro-proliferative effects of the p30 isoform. Nevertheless, how the increased levels
of C/EBPα promote the more aggressive disease in our Notch1-induced T-ALL models
remains to be determined.
In summary, we show that Trib2 absence does not have gross effects on mouse develop-
ment, and in particular on T cell development. This suggests that in some contexts, therapeuti-
cally targeting Trib2 may be a well-tolerated treatment strategy. However, our studies also
describe a new role for Trib2 in the pathogenesis of T-ALL by a mechanism that may involve
increased C/EBPα expression. Although our data clearly show that Trib2 absence enhances the
severity of Notch1-induced murine T-ALL, additional studies are required to determine the
relevance of these findings to human T-ALL.
TLX1+ (B) and LYL1+ (C), but not TAL1+ (D), adult T-ALL molecular subtypes in samples with low and high TRIB2 expression, respectively
(FDR < 0.05). E) Pediatric T-ALL samples with low (mean-SD and high (mean+SD) TRIB2 gene expression (average of 202478_at and 202470_s_at)
were identified in the GSE26713 dataset. Dashed lines indicate mean-SD and mean+SD of TRIB2 gene expression. F, G) GSEA analysis shows
enrichment of gene signatures of the TLX1+ (F) and LYL1+ (G), but not TAL1+ (H), pediatric T-ALL molecular subtypes in samples with low and high
TRIB2 expression, respectively (FDR < 0.05). NES, normalized enrichment score.
doi:10.1371/journal.pone.0155408.g007
Trib2 Suppresses T-ALL
PLOS ONE | DOI:10.1371/journal.pone.0155408 May 18, 2016 12 / 18
Materials and Methods
Animals
To generate the Trib2 null mice, a 129S7/SvEv BAC clone, which covers the entire TRIB2 geno-
mic locus, was obtained from the Sanger Institute (http://www.sanger.ac.uk/). The BAC recom-
bineering system was utilized to construct a targeting vector (http://recombineering.ncifcrf.
gov/) [48]. Two loxP sites were inserted to sandwich exon2. The FRT-flanked Neomycin cas-
sette was cloned downstream of the 3’ loxP site. TL1 ES cells were electroporated with the line-
arized targeting vector. Homologous recombinants were screened with a combination of PCR
and Southern blotting. Once germline transmission was observed, the mice were mated with
FLP1-transgenic mice (B6;SJL-Tg(ACTFLPe)9205Dym/J, The Jackson Laboratory) to remove
the Neomycin cassette. The flippase gene was bred out in the subsequent matings. The mice
were then backcrossed to the C57BL/6 background for more than 8 generations. All mice were
housed in specific pathogen-free facilities at the University of Pennsylvania. Experiments were
performed according to the guidelines from the National Institutes of Health with approved
protocols from the University of Pennsylvania Animal Care and Use Committee. The Body
Condition Score Index (BCSI) [49] was an important criterion for monitoring the health of the
mice. Mice were monitored at least three times per week and euthanized by CO2 inhalation fol-
lowed by cervical dislocation.
Bone marrow transduction and transplantation
Bone marrow cells were collected from 6- to 12-week-old mice 4 days after intravenous
administration of fluorouracil (5-FU) (250 mg/kg). The cells were cultured overnight in the
presence of IL-3 (6 ng/ml), IL-6 (5 ng/ml), and SCF (100 ng/ml). The cells were then washed,
resuspended in media containing cytokines and 4 μg/mL hexadimethidrine bromide (Sigma).
Retroviral supernatants, normalized by titer, were added and the cells were centrifuged at
1,290 g for 90 minutes. A second round of spinoculation was performed the following day.
After washing with PBS, at least 5 × 105 cells were injected intravenously into lethally irradi-
ated (9 Gy) recipients. For secondary recipients, 2x106 sorted, GFP+ splenocytes were injected
into sublethally irradiated (5 Gy) recipients. Mice were maintained on antibiotics in the drink-
ing water for 2 weeks after BMT. Mice were bled every 2 weeks to monitor blood counts and
evaluate the presence of circulating immature T cell progenitors by flow cytometry. Mice with
a body condition score of 2 [49] and decreased mobility were euthanized and tissues were
harvested for analysis.
Serial fluorouracil treatment
Mice received an intravenous dose of 5-FU on Day 0 (250mg/kg), Day 7 (150mg/kg) and Day 14
(150mg/kg). Mice with a body condition score of2 and decreased mobility were euthanized.
Constructs and retroviruses
Production of high-titer virus was performed as described previously [50, 51]. Lentiviral
pLKO.1 shRNA constructs were co-transfected into 293T/17 cells (ATCC, CRL-11268) with
pMDL (gag-pol), pRSV-Rev and pHIT123 (envelope). Retroviral constructs were co-trans-
fected into 293T cells with pCGP (gag-pol) and pHIT123 (envelope). Viral titers were deter-
mined using 3T3 fibroblasts. Viral supernatants were stored at -80°C.
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Cell culture and transduction
All cell lines were maintained in RPMI 1640 (Cellgro) supplemented with 10% fetal bovine
serum (FBS) (Hyclone), 1% penicillin/streptomycin (Gibco), 1% L-glutamine (Gibco) and
100 μM 2-mercaptoethanol (Sigma). Cells were centrifuged with viral supernatant and 8 μg/
mL hexadimethidrine bromide (Sigma) at 1,290 g for 90 min at 25°C. The cells were analyzed
or sorted at the indicated times after transduction. For growth curves, 5x104 cells were seeded.
Cells were counted over time. Cell density was maintained at 1x106 cells/ml.
Flow cytometry and cell sorting
For the analysis of primary mouse cells, bone marrow, blood thymocytes and splenocytes were
harvested and resuspended in PBS supplemented with 2% heat-inactivated FBS (Gibco). Anti-
bodies used for cell surface staining (all obtained from eBiosciences except where noted) were
CD3 (145-2C11), CD19 (1D3), CD4 (RM4-5), CD8 (53–6.7), CD25 (PC61; Biolegend), CD44
(IM7), Thy1.2 (53–2.1), CD11b (M1/70) and Gr-1 (RB6-8C5). Dead cells were excluded from
analyses with 4',6-diamidino-2-phenylindole (DAPI). To detect Annexin V, Jurkat cells were
stained following the manufacturer’s protocol. Briefly, an equal number of cells were resus-
pended in Annexin V binding buffer (10 mMHepes pH 7.4, 140 mMNaCl, 2.5 mM CaCl2)
with Annexin V antibody and incubated at room temperature in the dark for 15 minutes.
The cells were then stored on ice and analyzed immediately. Cells were run on an LSR II flow
cytometer (BD) and analyzed with FlowJo software v9.7 (TreeStar).
For cell sorting, primary splenocytes or cell lines were resuspended in PBS supplemented
with 2% FBS, 1% penicillin/streptomycin and DAPI (for the exclusion of dead cells). GFP+
cells were sorted on a BD FACS Aria II using a 70μm nozzle at 70psi.
Quantitative PCR
RNA was extracted using TRIzol. cDNA was synthesized from RNA with the SuperScript III
kit (Invitrogen). Transcripts were amplified with Taqman PCR master mix (Applied Biosys-
tems), and qPCR was performed on the ABI ViiA 7 system (Applied Biosystems). mRNA
quantities were normalized to 18S. Primer/probe sets to Trib2 (Mm01270457_m1) and 18S
(4319413E) were purchased from Life Technologies.
Immunoblotting
Whole-cell lysates were prepared with RIPA buffer supplemented with protease inhibitors
(Roche), NaF (10mM), PMSF (1mM) and Na3VO4 (1mM) or cells were directly lysed in SDS
sample buffer. Proteins were separated using SDS-PAGE and transferred to PVDF membranes.
Antibodies used for immunoblot from Cell Signaling Technology were pS473 AKT (4051),
AKT (4691), pT202/Y204 ERK (9101), ERK (9102), Trib2 (13533), and C/EBPα (8178). The
antibody against TAL1 was purchased from Santa Cruz Biotechnology (sc-12984). β-actin
(A5316; Sigma) was used as a loading control. Secondary anti-mouse-HRP (NA931V) and
anti-rabbit-HRP (NA934V) were obtained from GE Healthcare. Blots were visualized with
SuperSignal west pico chemilumenscence (34080; Thermo Scientific) or SuperSignal west
femto chemilumenscence substrate (34095; Thermo Scientific).
Histology
Freshly dissected organs were fixed in 10% neutral buffered formalin, paraffin embedded, sec-
tioned, and stained with hematoxylin and eosin. Images were captured using an Olympus
BX41 or a Nikon Eclipse Ni microscope.
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Microarray data analysis
CEL files from GSE15907, Immunological Genome Project data Phase 1 [52], were normalized
using robust multichip average (RMA) with the Bioconductor [53] “affy” package [54]. The
normalized expression values of Trib2 in different T cell subsets were plotted in GraphPad
Prism. Variation between biological replicates is indicated using a box and whisker plot.
GSEA analysis
The microarray-based gene expression measurements of human T-ALL samples were obtained
from the GSE13159 and GSE26713 datasets. The samples from GSE13159 were GCRMA back-
ground adjusted, quantile normalized, PM corrected and batch corrected [53]. The samples
from GSE26713 were normalized using RMA. Based on the expression level of TRIB2 (average
of TRIB2 probes 202478_at and 202470_s_at) the low and high expressing TRIB2 T-ALL
groups were identified as the samples with less than mean-SD or higher than mean+SD TRIB2
expression, respectively. Standard GSEA analyses were performed using the gene sets defined
in C2:CGP collection of MSigDB V5.1.
Statistical analysis
All statistical analyses were performed using GraphPad Prism.
Supporting Information
S1 Fig. Loss of Trib2 does not affect hematopoietic stem cells. A) Flow cytometry was used to
assess the presence of lineage−Kit+Sca-1+ (LSK) hematopoietic progenitors and lineage−Kit+Sca-
1+CD150+CD48− (LSK SLAM) hematopoietic stem cells in the bone marrow of Trib2+/+ and
Trib2-/- mice. Representative plots are shown B) The average percentage of LSK and LSK SLAM
cells in the bone marrow of Trib2+/+ and Trib2-/- mice is shown (n = 3 per group). C) Kaplan-
Meier curve of mice serially injected with 5-FU. Mice received an intravenous dose on Day 0
(250mg/kg), Day 7 (150mg/kg) and Day 14 (150mg/kg). Mice with a body condition score of
2 and decreased mobility were euthanized (n = 5 per group; p = 0.06).
(EPS)
S2 Fig. MigR1 does not affect hematopoietic reconstitution of lethally irradiated recipients.
A) Flow cytometry was used to assess the immunophenotype of GFP+ cells in the spleen. B)
The percentage of each cell type in the spleen is shown.
(EPS)
S3 Fig. Kaplan-Meier curves of sublethally irradiated secondary recipients reconstituted
with 2 x106 sorted Trib2+/+ or Trib2-/- tumor cells isolated from primary recipients express-
ing A) ICN1 (n = 15 per group; “”, p = 0.0217), or B) L1601PΔP (n = 5 Trib2+/+ recipients,
n = 10 Trib2-/- recipients; “”, p = 0.0005).
(EPS)
S4 Fig. Trib2 is a transcriptional target of Notch1 in TAL-130, but not Jurkat, cells. A) Jur-
kat, or B) TAL-130 cells were treated with 1μM of the GSI Compound E or DMSO for 48
hours and then the GSI was “washed out” and replaced with DMSO to permit Notch signaling.
After 4 hrs, RNA was isolated and subjected to reverse transcription followed by quantitative
PCR to determine the expression levels of Trib2 or Hes1 relative to EF1α.
(EPS)
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